New CAR T therapy for relapsed and refractory ALL

IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma

The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blinatumomab

MINDACT long-term results: 70-gene signature MammaPrint to guide adjuvant chemotherapy use in breast cancer

CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer

Early safety from a trial of talimogene laherparepvec (T-VEC) injected into liver tumours plus pembrolizumab

Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma

Background of the KEYLYNK-007 trial for advanced solid tumours

US MM-6: Long-term proteasome inhibition in multiple myeloma following an in-class transition from bortezomib to ixazomib

Regulating haematopoietic stem cell dormancy and ageing through the netrin-1-neogenin axis

Enasidenib plus azacitidine vs azacitidine monotherapy in mutant-IDH2 ND-AML

Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics